


Sai D. Prasad

Executive Director – Bharat Biotech  
Board Chair - DCVMN

Road Map to Future Vaccines  
Session 1  
22 Oct 2022



## GROUP COMPANIES




## Learning Agenda : From COVID to other vaccines

- Experience and expertise gained in fast track product development, scale up, large scale distribution,
  - Could be applied to other vaccines, based on appropriate conditions,
- Aggressive product development funding, purchase commitments, etc should be emulated for other high risk vaccines,
- If carefully determined; excess manufacturing capabilities could be repurposed and deployed for other high demand vaccines,
- Platform technologies could be deployed for other targets,

- Variance in ability of vaccine companies to develop, manufacture COVID vaccines,
- ~ > 5% of companies were able to innovate, develop or manufacture vaccines for COVID,
- Most of the companies that were able to respond to the pandemic were able to do so, based on decades of expertise in .....

  - R&D / Innovation capabilities,
  - Manufacturing platform technologies,
  - Product development expertise,
  - Large scale manufacturing expertise
  - Etc..

# COVID Vaccines : Bharat Biotech Experience Platform Technologies



# COVID Vaccines : Experience

- Globally > 15 billion doses manufactured
- > 20 EUL / EUA / Licensed vaccines
- Unprecedented
  - Risk
  - Investments
  - Product development speed
  - Fast Track regulatory approvals
  - Advance procurement commitments
  - Product development funding
- Bharat Biotech : Experience
  - Fast Track regulatory approvals
  - No development funding or advance procurement commitments
  - All initial investments from internal resources

## Future Challenges for Vx manufacturers

---

- Maintenance and Management of expanded manufacturing base
- Losses due to Over stocks of raw materials, packing materials, consumables etc, due to expiry prior to use
- Destruction of expired vaccines, losses to vaccine manufacturers
- Delayed development of other vaccine candidates
- Sudden increase in post pandemic demand for other vaccines resulting in supply shortages
- Lack of ready availability of raw materials, packing materials, consumables etc,

# Bharat Biotech : Experience



- Technology / Expertise
  - Algel + IMDG novel Adjuvant
  - Scale up expertise of inactivated vaccines, ~ 100 million doses / month
- Losses
  - Unused / Expired stocks of DS and DP,
  - Unused / Expired stock of RM, PM and consumables,



- Technology / Expertise
  - Intranasal delivery platform
  - Platform technology for other targets
- No demand / No return on investments







THANK YOU